New Revision of MDCG 2020-16 Guidance on IVD Classification: Key Updates in Version 4
The Medical Device Coordination Group (MDCG) published Revision 4 of its guidance document MDCG 2020-16, titled "Guidance on Classification Rules for in vitro Diagnostic Medical Devices under Regulation (EU) 2017/746". This updated version provides further clarification on the application of the classification rules outlined in Annex VIII of the IVDR.
As the European Authorised Representative for many IVD manufacturers, MedNet EC-REP supports its clients in understanding and implementing these regulatory updates. Below, we highlight the main changes introduced in Revision 4 and what they mean for IVD manufacturers placing products on the EU market.
Whatโs New in Revision 4?
The main changes in this revision concern the SARS-CoV-2 tests. They are now no longer classified in class D, but in class C in the case of self-tests and in class B in the case of tests for professional use. This is reflected in the amended examples for Rule 1 (second indent), Rule 4 and Rule 6.
With this revision, the MDCG continues its effort to improve regulatory clarity and support consistent implementation across the EU. Manufacturers are encouraged to review the updated guidance in detail and assess whether any of their products may be affected by the revised interpretation of classification rules.
Download the full Document: MDCG 2020-16 rev.4
Latest news
Implications of the Update to the Borderline & Classification Manual under MDR and IVDR
On 12 September 2025, the European Commission published Version 4 of the Manual on Borderline and Classification under Regulations (EU) 2017/745 and 2017/746, developed by the Borderline and Classification Working Group (BCWG).
Regulatory Affairs Bulletin: Intended Purpose vs Intended Use under MDR & IVDR
European regulations EU 2017/745 (MDR) and EU 2017/746 (IVDR) require precise definitions in technical documentation, and the distinction (or overlap) between intended purpose and intended use remains a topic of operational significance.
-250x250.jpg&w=256&q=75)
MedNet EC-REP GmbH at MEDICA 2025 โ Visit Us in Hall 3, Booth D43
MedNet EC-REP GmbH is pleased to announce that we will once again be exhibiting at MEDICA 2025 in Dรผsseldorf, the worldโs leading trade fair for the medical technology industry.
EU eIFU Regulation Update Draft: What Medical Device Professionals Need to Know
The European Commission has introduced a significant amendment to Implementing Regulation (EU) 2021/2226, impacting how medical device manufacturers provide instructions for use (IFU).
Understanding the Interplay: MDR, IVDR, and the AI Act โ Key Insights from MDCG 2025-6
Recently, the MDCG, in conjunction with the Joint Artificial Intelligence Board (AIB), released the MDCG 2025-6 FAQ document, offering essential clarifications on the interplay between the MDR, the IVDR, and the Artificial Intelligence Act (AIA).
Navigating IVDR and MDR Performance Studies: Key Insights from MDCG 2025-5 Q&A
The European Medical Device Coordination Group (MDCG) has released its latest guidance, MDCG 2025-5, a comprehensive Questions & Answers document addressing performance studies for in vitro diagnostic medical devices (IVDs) under Regulation (EU) 2017/746 (IVDR).
MDCG 2019-11 Rev.1: Important Changes for Medical Device Software Developers
In the dynamic world of medical device regulation, staying abreast of the latest guidance is paramount for manufacturers. The Medical Device Coordination Group (MDCG) has recently released a significant update to its MDCG 2019-11 guidance document, now designated as MDCG 2019-11 Rev.1.
MDCG 2025-4: Key Guidance for Medical Device Software on Online Platforms
The European Commission's Medical Device Coordination Group (MDCG) has released the MDCG 2025-4 guidance document, titled "Guidance on the safe making available of medical device software (MDSW) apps on online platforms."